Qiagen N.V. Product Pipeline Analysis

Publication Date	August 2008
Publisher	Global Markets Direct
Product Type	Report
Pages	43
ISBN Number	not applicable
Product Code	GMD04754

Price

£400.00
approximately: $747 | €507

PDF

Order above formats by FAX

Summary

This report is an insightful source for data, analysis and strategic insights into a Qiagen N.V.'s pipeline and investigational products. The report also provides details on clinical trials covering trial phase, description, investigator information, primary and secondary end-points and trial results for products in development.

Scope

Details of development stage by sector and equipment type.
Pipeline products grouped by therapy area, development stage and trial phase.
Detailed information on clinical trials covering trial phase, description, investigator .nformation, primary and secondary end-points and trial results.
Trial updates, trial start and end dates, patient numbers and the trials primary outcome measures, secondary outcome measures.
Product updates covering estimated approval dates and estimated launch dates.
Descriptions of novel technologies relating to pipeline products of the company.
Patents and patent applications covered for the product.
News updates on key events relating to the product and its development.

Reasons to buy

A single source to fulfill competitor information relating to products in development.
Identify pipeline products that are potential competitor to your product lines.

Understand a company's strategic position by accessing detailed independent intelligence on its product pipeline.

Access clinical trial information to map trial results and plan targeted marketing activities.
Take corrective measures on your own development programs and R&D initiatives based on regulatory events of competitor product pipelines.
Identification of potential investment opportunities.
Build up knowledge base for potential distribution and marketing partners.
Helps avoid patent infringement.
Timelines from concept to market lets you keep track of market potential build for a new product.

Assess a company's future growth by determining its pipeline depth, for probable acquisition opportunities.

Content

1 List of Tables
- 1.2 List of Figures
2 Company Snapshot
- 2.1 Key Information
- 2.2 Company Overview
- 2.3 Financial Performance
- 2.4 Industry Outlook In Vitro Diagnostics
3 Business Description
- 3.1 Business Overview
- 3.2 Major Products and Services
  - 3.2.1 Overview
4 History
5 Competitors
6 Key Employees
7 Key Employee Biographies
8 Company Statement
9 Locations And Subsidiaries
- 9.1 Head Office
- 9.2 Other Locations & Subsidiaries
10 Recent Developments
- 10.1 Strategy And Business Planning
  - 10.1.1 Feb 22, 2008: Qiagen Opens New Service Solutions Center In Singapore
  - 10.1.2 Dec 03, 2007: QIAGEN, Bio*One Establish Dx Assays
- 10.2 Financial Announcements
  - 10.2.1 May 05, 2008: Qiagen Reports Q1 2008 Results
  - 10.2.2 Feb 11, 2008: Qiagen Reports Q4 2007 Results
  - 10.2.3 Nov 05, 2007: Qiagen Reports Q3 2007 Results
  - 10.2.4 Aug 06, 2007: Qiagen Reports Q2 2007 Results
  - 10.2.5 May 07, 2007: Qiagen Reports Q1 2007 Results
  - 10.2.6 Feb 12, 2007: Qiagen Reports Fiscal Year-End 2006 Results
  - 10.2.7 Nov 13, 2006: Qiagen Reports Q3 2006 Results
  - 10.2.8 Aug 07, 2006: Qiagen Reports Q2 2006 Results
- 10.3 Research And Development
  - 10.3.1 Dec 03, 2007: QIAGEN, Bio*One Establish Dx Assays
- 10.4 Corporate Communications
  - 10.4.1 May 13, 2008: Qiagen Appoints VP, Molecular Diagnostic Sales For EMEAA
- 10.5 Product News
  - 10.5.1 Feb 14, 2008: QIAGEN And Center For Molecular Medicine Create Research Collaboration For Molecular Diagnostic Markers For Breast Cancer, Other Women's Health Issues
  - 10.5.2 Nov 08, 2007: Study Finds New Version Of QIAGEN's HPV Test For Developing Countries Could Reduce Risk Of Cervical Cancer By More Than Half When Combined With Appropriate Treatment
- 10.6 Clinical Trials
  - 10.6.1 Nov 08, 2007: Study Finds New Version Of QIAGEN's HPV Test For Developing Countries Could Reduce Risk Of Cervical Cancer By More Than Half When Combined With Appropriate Treatment
- 10.7 Other Significant Developments
  - 10.7.1 Dec 19, 2007: QIAGEN, Ventana Announce Settlement Of Patent Dispute
11 Qiagen N.V. Pipeline Products
- 11.1 Qiagen N.V. Product Pipeline Analysis
  - 11.1.1 Qiagen N.V. Pipeline Products By Equipment Type
  - 11.1.2 Qiagen N.V. Pipeline Products By Development Stage
  - 11.1.3 Qiagen N.V. Pipeline Products By Therapy Area
  - 11.1.4 Qiagen N.V. Pipeline Products By News Summary
- 11.2 FastHPV
  - 11.2.1 Product Description
  - 11.2.2 Product Status
  - 11.2.3 Product Milestone
- 11.3 Genotyping Test
  - 11.3.1 Product Description
  - 11.3.2 Product Status
- 11.4 Breast cancer biomarkers
  - 11.4.1 Product Description
  - 11.4.2 Product Status
  - 11.4.3 Product Milestone
12 Appendix
- 12.1 Methodology
  - 12.1.1 Coverage
  - 12.1.2 Secondary Research
  - 12.1.3 Primary Research
  - 12.1.4 Expert Panel Validation
- 12.2 Contact Us
- 12.3 About Global Markets Direct
- 12.4 Disclaimer
1 List of Tables
- Table 1: Qiagen N.V.,Key Facts
- Table 2: Qiagen N.V., Key Employees,
- Table 3: Qiagen N.V., Other Locations
- Table 4: Qiagen N.V., Subsidiaries
- Table 5: Qiagen N.V. Pipeline Products by Equipment Type
- Table 6: Qiagen N.V. Pipeline Products By Development Stage
- Table 7: Qiagen N.V. Pipeline Products By Therapy Area
- Table 8: Qiagen N.V. Pipeline Products By News Summaries
- 1.2 List of Figures
- Figure 1: Qiagen N.V. Pipeline Products By Equipment Type
- Figure 2: Qiagen N.V. Pipeline Products By Equipment Type
- Figure 3: Qiagen N.V. Pipeline Products By Development Stage
- Figure 4: Global Markets Direct Methodology